FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Sponsor
Fudan University
Study ID
NCT04832776
Phase
PHASE2
Status
Unknown

Conditions

  • Liver Metastasis Colon Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Cetuximab — DRUG
    one group plus cetuximab
  • Bevacizumab — DRUG
    one group plus bevacizumab
  • FOLFOXIRI — DRUG
    FOLFOXIRI

Study Details

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

Key Dates

First listed
Apr 6, 2021
Start date
Apr 17, 2021
Status verified
Apr 2021
Primary completion
Dec 31, 2023
Completion
Dec 31, 2025

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: FOLFOXIRI+C225
  • Active Comparator: FOLFOXIRI+BEV

Primary Outcome Measure

ORR [ Time Frame: up to 8 weeks ]

Central Contacts

Related Studies